Spectroscopy in Parkinson Disease (SPIN-PD)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01005030 |
Recruitment Status
: Unknown
Verified November 2009 by Molecular Biometrics, Inc..
Recruitment status was: Enrolling by invitation
First Posted
: October 30, 2009
Last Update Posted
: November 10, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Parkinson Disease | Other: Blood draw |
Study Type : | Observational |
Estimated Enrollment : | 500 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Evaluation of Blood Biospectroscopy as a Novel Diagnostic Test for Idiopathic Parkinson Disease |
Study Start Date : | October 2009 |
Estimated Primary Completion Date : | March 2013 |
Estimated Study Completion Date : | March 2014 |

Group/Cohort | Intervention/treatment |
---|---|
PostCEPT Subjects
Subjects with current Parkinson Disease Diagnosis currently enrolled in PostCEPT study
|
Other: Blood draw
Blood draw, two tubes, used for isolation of cell-free blood plasma
|
Control Subjects
Non-blood relatives of PostCEPT Subjects matched for age and other demographics
|
Other: Blood draw
Blood draw, two tubes, used for isolation of cell-free blood plasma
|
- The primary outcome of the study is the correct classification of cases of PD and controls. This will be quantified as sensitivity and specificity. [ Time Frame: Baseline and annually for two years ]
- Determine impact of disease stage, age, gender, medications, cognitive scores, other laboratory measures (e.g. alpha-synuclein) and other clinical/demographic variables on plasma biospectra. [ Time Frame: Baseline and annually for two years ]
- Correlate plasma biospectra with dopamine transporter neuroimaging data. [ Time Frame: Baseline and annually for two years ]
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 46 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
PD Subjects:
- PostCEPT subjects with a diagnosis of PD based on UK Brain Bank criteria.
- Willing and able to provide informed consent.
Healthy Controls:
- No current diagnosis or known history of a neurological disease/disorder.
- Non-blood relative of a patient or subject at the site who has diagnosis of PD (may include healthy controls from the PROBE study).
- No first degree relatives with diagnosis of PD
- MoCA score > 26.
- Age > 45.
- Willing and able to provide informed consent.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01005030
United States, New York | |
University of Rochester | |
Rochester, New York, United States, 14620 |
Principal Investigator: | Bernard Ravina, MD | University of Rochester | |
Principal Investigator: | Anthony E Lang, MD | University of Toronto |
Additional Information:
Publications:
Responsible Party: | Bruce J. Goldstein / Vice President, Operations, Molecular Biometrics, Inc. |
ClinicalTrials.gov Identifier: | NCT01005030 History of Changes |
Other Study ID Numbers: |
MB_PD001 |
First Posted: | October 30, 2009 Key Record Dates |
Last Update Posted: | November 10, 2009 |
Last Verified: | November 2009 |
Keywords provided by Molecular Biometrics, Inc.:
Parkinson Disease blood plasma |
metabolomics spectroscopy oxidative stress. |
Additional relevant MeSH terms:
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases |
Central Nervous System Diseases Nervous System Diseases Movement Disorders Neurodegenerative Diseases |